StemX Bio develops 3D human micro-tissues that replicate diseases more accurately than animal testing, enabling faster and safer drug development.
StemX Bio has raised €350k across 1 funding round from 1 investor, most recently a round in Oct 2025. Based in Leiden, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-10 | Other | €350k |
| UNIIQ |
| View deal → |
